I wouldn't claim to know any more about what's going to
I wouldn't claim to know any more about what's going to happen on Wednesday's call than anyone else. I bought in around February of 2019 and have continued to increase my shares with the exception of a small amount I sold to cover the cost of some home renovations. I'm up a good bit. Even after the great bull*$#& collapse from $10 to $3-ish, because I'm an expert investor*.
*Not true about being an expert, just lucky I think
So what do I think is going to happen on the call Wednesday? Great question and thank you so much for asking me...
Details of the current discussions with MHRA in regards to fast track approval for COVID-19
Would it be written that way if the MHRA had already told us to bugger off?
(Please award me appropriate points for using "bugger", which I'm only 85% sure is a term used in the UK. Bollocks if not.)
I still think this is the best possible route to revenue at this moment. They developed NEWS2 and we crushed it. They also have a good bit of Covid still. I'm no mathematishionist* but that adds up to a win in my book. I'll also wager that they're at least a little less corrupt than the FDA and can see a f*$&ing gift horse when it presents itself. Also don't sleep in Israel. They wouldn't normally be in the top 5 of countries approached so there are reasons and relationships driving that which can make all the difference.
*Medical term
Status of Emergency Use Approval for COVID-19, CD10 trial in U.S.
I believe this portion of the call will go like this:
NP: The FDA has been amazing so far and they have asked us for some data around the trial that we are providing by sometime next week. After we submit that data we expect feedback within 1-2 weeks and we are thankful for the (corrupt and pathetic*) FDA's efforts in helping bring this important product to market. Can-kicking down the road in other words.
*My words, but I think we an all agree that there's some shenanigans occurring right now within the FDA
Detail discussions of the cancer results and discussions from invited guest (from Creative MicroTech) on the leronlimab potential in all cancers based on current results in the last 1 year
This is actually pretty exciting. Aren't we awaiting a breakthrough designation on the basket cancers? They, meaning Creative MicroTech, have apparently been involved for a little while now and if patients are continuing to end up with 0 circulating tumor cells than watch out!
HIV – BLA submission in U.S. and U.K.
Spoiler alert because Cytodyn wants it and they've asked for it and they've not been responded to yet. At least in the US. Try to keep it in your pants as we don't get any substantial news on this front from the states. But maybe we get a nugget or two from the UK. I mean, for crying out loud the evidence is substantial at this point. We just need someone who isn't "conflicted" to look at it.
HIV – cure project
How great would it be if they've already injected a few patients?! I know this kind of trial depends on when they're scheduled for their transplant but I have to imagine this makes all the news sites if it's successful so I'm anxious to see it get underway.
NASH timeline
I think they're finally ready to start really sinking money into this. Sucks that a fully funded, revenue generating company would have probably been further along but we aren't here to turn a $79/share stock into $94. We're trying to usher this "penny" OTC stock into the stratosphere for a much greater return. Dem's the breaks.
Potential other trials
Clearly it's not anything of substance if we're just talking "potential". I'd love an MS or Alzheimer's trial as much as the next guy but I'm banking on the fact that these sorts of things are too fringe to be happening any time soon.
Scientific Advisory Board
Wait! We have a science board?! I had no idea!!!
Kidding, of course. This is a tremendous idea that will pay off significantly over time. I can't imagine there's any meat on this bone right now though,as they just started announcing people. I'm guessing we just added another one or two people at this point.
NASDAQ uplist
People really have their you know what's in a wad over this. Nasdaq folks appear to be behind their traditional timelines right now. But even then they explain publicly that the time for the company to respond to questions is a 1-2 week process and the time that NASDAQ takes to process that information is another 1-2 weeks. So we are well within that timeframe and looking at another week or so before we can reasonably expect an answer without any other variables getting involved.
But here's the thing. We qualify. There's no reason we shouldn't be accepted. Same for HIV BLA. We qualify. There's no real reason we shouldn't be accepted.
When it comes to Covid I'm as annoyed as the rest of you about exposure but consider that almost nobody posting about Covid treatments is really an expert about what's going on. If you start googling monoclonal antibodies you will find a lot of information about everything but Leronlimab. Hell, even stat news has an article on the first page because they understand how to abuse the system and show up in searches. People who do the laziest of DD will not easily find Cytodyn or learn much of substance about Leronlimab. It perpetuates itself.
The MINUTE we get an authorization in another country (which is my prediction for how it will go, by the way) we will be contracting with them to sell over 1 BILLION DOLLARS in inventory. That's all we need. The media will follow. The share price will rise. The approvals will follow. The share price will rise. The reserving/purchase of 2021's stock will happen and that will be far more than 1 Billion dollars. The share price will rise. The agreements to increase production will happen. Me spending an absurd amount of money on a bottle of wine to celebrate will happen. Gloating to AF on twitter and calling him a failed Dbag will happen. You get the point. I'll be drunk and pretending like I knew all along exactly how it would go while conveniently forgetting that I predicted we'd be at $20+ weeks ago.
Long. Strong. And about to get the friction on.
47
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
ViewScan's Latest Step in AI-Powered Monitoring Long Island's own ViewScan just kicked up some dust in the AI-based monitoring scene. This outfit is rolling out a new release of its ViewScan Protect software, fortified with advanced analytics aimed at beefing up security and operational efficiency. Now, before you gloss over this news as just another tech update, let me...
Continue Reading
iFranchise's Unyielding Dominance in Franchise Consulting Five seconds in the franchise game, and you'd know that staying on top is a grind. But when you're iFranchise Group, it seems like the eighth time is the charm—if there ever was a need for luck. These folks have secured the number one spot in Entrepreneur magazine's Top Franchise Suppliers ranking yet again....
Continue Reading
AI's New Role in Wealth Management Just when you think you've seen it all, along comes a partnership that shakes things up. Beemo Automation is teaming up with Choreo, a heavyweight in the tax-focused registered investment adviser world, to infuse some AI prowess where it matters. Choreographing their moves, they're looking to build something that's not just functional...
Continue Reading
CEER's Ambitious Leap in Automotive Innovation There's a new kid on the automotive block, and it's making some serious noise. Straight out of Jeddah, CEER has just taken the wraps off their flagship electric sedan and SUV, dubbed the EXOBOT. No small beans here—this is a full-throttle, Saudi-driven pitch into the global automotive circus. And why not? There's oil in...
Continue Reading
Pharmacy Certification Made Easy When ScriptSafe rolled out its certification service for pharmacies, it felt like the industry's straitjacket was finally coming off. We’re talking about a process that traditionally took months, cost a small fortune, and made pharmacies fill out forms like they were honing a doctoral thesis. But now, you've got ScriptSafe offering a...
Continue Reading
Reimagining Streaming: GRAI Buys Hangout FM The music streaming game has just been dealt a fresh hand. GRAI, an AI-driven music company, has snatched up Hangout FM, looking to ignite a social revolution in how we experience music. Sitting here, I'm thinking about all those playlists we've built but never truly shared. This acquisition might just change that by combining...
Continue Reading
A Fresh Chapter for Half Moon Cay Mark it down, folks—Holland America Line is shaking things up over at RelaxAway, Half Moon Cay. The cruise line, known for its deep roots in premium cruising, is pouring resources into its private island playground to celebrate its 30th anniversary in 2027. And the timing couldn't be more calculated, what with peak cruise season around...
Continue Reading
A Fresh Start for Young Careers with CareerPath You remember the time in life when we thought just having a degree meant something? Well, the game’s changed, and now it’s a twisted jungle where young folks struggle to find their footing. Partners International, a name I’m no stranger to—known for their human capital wizardry—seems to have noticed this chaotic...
Continue Reading
Pioneering Leadership for Children's Brain Tumor Network In a world where every advance in pediatric oncology can make a measurable difference, the Children's Brain Tumor Network (CBTN) has just unveiled quite the ace up its sleeve: Dr. Sarah Leary. She's stepping in as Co-Chair of its Executive Board, taking the reins alongside Brian Rood, MD. With extensive experience...
Continue Reading
Remember the days when the FBI felt like a mythical fortress of surveillance and high-tech wizardry? Today, we're seeing one of its key veterans, Marcus Thomas, take a different path—a path that's as gritty and necessary as any Wall Street hustle. He's jumping onto the board of Re-fined, a Denver nonprofit aiming to give survivors of sexual exploitation and human...
Continue Reading
Top 5 Most Recently Viewed Articles
Walmart's Emission Reduction Challenges for 2025 and 2030 Walmart (NYSE: WMT) has recently announced that it is likely to face significant challenges in meeting its ambitious climate targets for 2025 and 2030. The retail giant has pledged to reduce greenhouse gas emissions from its operations by a substantial 35% by 2025 and an impressive 65% by 2030, using 2015 levels as...
Continue Reading
MiTAC Computing Showcases Innovative Solutions at OCP APAC Summit MiTAC Computing Technology Corporation, a prominent player in server platform design and manufacturing, showcased its latest innovations at the OCP APAC Summit. Their AI-optimized compute and GPU servers exemplify a commitment to creating sustainable and efficient data centers. Attendees at the event were...
Continue Reading
The Irreplaceable Edge of Human Creativity in the Era of AI In a compelling new episode from the Planet Classroom Network, the focus shifts to why human imagination remains an essential asset amidst the backdrop of escalating artificial intelligence integration in our lives. Hosted by C.M. Rubin, this episode, titled "Human Creativity: Our Edge in the AI Era," features...
Continue Reading
Absolute Security Recognized in ZTE Landscape Report Absolute Security, a notable leader in enterprise resilience, has recently caught the attention of industry analysts for its impressive standing in the Zero Trust Edge (ZTE) landscape. The recognition comes from leading analyst organization Forrester in their detailed report on the topic, titled The Zero Trust Edge...
Continue Reading
Understanding the Current Market Dynamics As we look across the financial landscape, signs indicate a promising trajectory for small-cap stock performance. The momentum has picked up over the trailing month as optimism returns with glimmers of potential shifts in Federal Reserve interest rate policy. As trading week comes to a close, the overall market sentiment has...
Continue Reading